FT
REGN icon

Fiduciary Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Fiduciary Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.55M Buy
8,478
+12
+0.1% +$9.19K 0.08% 138
2025
Q4 		$6.53M Buy
8,466
+615
+8% +$418K 0.07% 144
2025
Q3 		$4.41M Buy
7,851
+289
+4% +$163K 0.05% 190
2025
Q2 		$3.97M Sell
7,562
-406
-5% -$227K 0.05% 197
2025
Q1 		$5.05M Sell
7,968
-238
-3% -$164K 0.07% 168
2024
Q4 		$5.85M Sell
8,206
-316
-4% -$265K 0.08% 150
2024
Q3 		$8.96M Buy
8,522
+26
+0.3% +$28.9K 0.13% 112
2024
Q2 		$8.93M Buy
8,496
+58
+0.7% +$56.2K 0.13% 107
2024
Q1 		$8.12M Hold
8,438
– – 0.12% 118
2023
Q4 		$7.41M Buy
8,438
+1
+0% +$823 0.12% 115
2023
Q3 		$6.94M Sell
8,437
-43
-0.5% -$33.8K 0.13% 111
2023
Q2 		$6.09M Sell
8,480
-29
-0.3% -$22.4K 0.11% 131
2023
Q1 		$6.99M Sell
8,509
-152
-2% -$115K 0.13% 123
2022
Q4 		$6.25M Sell
8,661
-370
-4% -$273K 0.12% 132
2022
Q3 		$6.22M Sell
9,031
-6,859
-43% -$4.32M 0.13% 122
2022
Q2 		$9.39M Buy
15,890
+5
+0% +$3.25K 0.2% 99
2022
Q1 		$11.1M Sell
15,885
-126
-0.8% -$79.7K 0.2% 101
2021
Q4 		$10.1M Sell
16,011
-15
-0.1% -$9.22K 0.17% 110
2021
Q3 		$9.7M Buy
16,026
+367
+2% +$228K 0.17% 108
2021
Q2 		$8.75M Buy
15,659
+297
+2% +$150K 0.17% 118
2021
Q1 		$7.27M Buy
15,362
+79
+0.5% +$38.5K 0.15% 131
2020
Q4 		$7.38M Buy
15,283
+1,918
+14% +$1.04M 0.15% 123
2020
Q3 		$7.48M Sell
13,365
-958
-7% -$581K 0.18% 104
2020
Q2 		$8.93M Buy
14,323
+527
+4% +$299K 0.22% 89
2020
Q1 		$6.74M Buy
13,796
+9
+0.1% +$3.71K 0.2% 99
2019
Q4 		$5.18M Buy
13,787
+4,721
+52% +$1.59M 0.12% 134
2019
Q3 		$2.52M Buy
9,066
+1,962
+28% +$581K 0.06% 184
2019
Q2 		$2.22M Buy
7,104
+1,635
+30% +$544K 0.06% 187
2019
Q1 		$2.25M Buy
+5,469
New +$2.25M 0.06% 183

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fiduciary Trust's REGN Position: Q1 2026 in Review

Fiduciary Trust increased its Regeneron Pharmaceuticals (REGN) stake by 0.14% in Q1 2026, buying an estimated $9.19K and bringing the position to 8,478 shares worth $6.55M. The position accounts for 0.08% of the portfolio, ranked #138.

Fiduciary Trust first reported a position in REGN in Q1 2019 and has held it in 29 quarters since. The position peaked at $11.1M in Q1 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Fiduciary Trust held 8,478 shares of Regeneron Pharmaceuticals worth $6.55M as of Q1 2026.
  • Fiduciary Trust bought 12 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $9.19K.
  • Regeneron Pharmaceuticals made up 0.08% of Fiduciary Trust's portfolio in Q1 2026, its #138 holding.
  • Fiduciary Trust first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Fiduciary Trust's Regeneron Pharmaceuticals position peaked at $11.1M in Q1 2022.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Fiduciary Trust's 13F filing for Q1 2026, filed 15 May 2026.